A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
暂无分享,去创建一个
F. Meric-Bernstam | S. Piha-Paul | A. Tsimberidou | T. Yap | H. Tran | V. Subbiah | V. Morris | S. Fu | J. Kawedia | D. Karp | M. B. Blum Murphy | S. Pant | Meng Gao | Joann Lim | B. Kee | C. Tseng